Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis

Figure 6

(a) WT% in patients with NCFB increased from baseline to 6 months in controls (); (b) effect of roxithromycin on WT% in patients with NCFB from baseline to 6 months of treatment (); (c) WA% in patients with NCFB increased from baseline to 6 months in controls (); and (d) effect of roxithromycin on WA% in patients with NCFB from baseline to 6 months of treatment ().

(a)

(b)

(c)

(d)